An investigation on behalf of investors of PetIQ, Inc. (NASDAQ: PETQ) shares over potential securities laws violations by PetIQ, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of PetIQ, Inc. (NASDAQ: PETQ) concerning whether a series of statements by PetIQ, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Eagle, ID based PetIQ, Inc. operates as a pet health and wellness company. PetIQ, Inc. reported that its annual Total Revenue rose from $266.68 million in 2017 to $528.61 million in 2018 and that its Net Loss declined from $3.49 million in 2017 to $0.78 million in 2018.

On April 30, 2019, a report was issued regarding PetIQ, entitled A Flea And Tick Infested Investment, asserting that the Companys stock was significantly overvalued due to the companys dubious past and questionable management team, among other issues. Specifically, the report alleged that PetIQs apparent predecessor . . . was accused of stealing hundreds of thousands of dollars worth of pet medication from vets before allegedly reincorporating as a registered subsidiary of True Science Holdings, later renamed PetIQ, and that True Science appears to have formed non-arms-length relationships with veterinary drug wholesalers through the first half of the 2010s, and was later accused of using these relationships to manufacture inflated assets and earnings.

Shares of PetIQ, Inc. (NASDAQ: PETQ) declined from $32.47 per share on April 8, 2019 to $23.06 per share on May 2, 2019.